Gates Foundation To Invest $52M In German Biotech Company, To Work Together To Develop Infectious Disease Vaccines

Reuters: Gates Foundation makes its biggest-ever equity investment in German biotech
“The Bill & Melinda Gates Foundation said it would invest $52 million in CureVac, a German biotechnology company that develops vaccines and immunotherapies, marking the foundation’s biggest-ever equity investment. … The foundation will also fund multiple projects developing vaccines for viral, bacterial, and parasitic infectious diseases that disproportionately affect people in the world’s poorest countries, apart from the equity investment…” (Grover, 3/5).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.